1.
Dvela-Levitt M, Kost-Alimova M, Emani M, et al. Small Molecule Targets TMED9 and Promotes Lysosomal Degradation to Reverse Proteinopathy. Cell. 2019;178(3):521-535.e23. doi:10.1016/j.cell.2019.07.002.
1.
Peng LF, Schaefer EAK, Maloof N, et al. Ceestatin, a novel small molecule inhibitor of hepatitis C virus replication, inhibits 3-hydroxy-3-methylglutaryl-coenzyme A synthase. J Infect Dis. 2011;204(4):609-16. doi:10.1093/infdis/jir303.
1.
Smith I, Greenside PG, Natoli T, et al. Evaluation of RNAi and CRISPR technologies by large-scale gene expression profiling in the Connectivity Map. PLoS Biol. 2017;15(11):e2003213. doi:10.1371/journal.pbio.2003213.
1.
Hideshima T, Bradner JE, Wong J, et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci U S A. 2005;102(24):8567-72. doi:10.1073/pnas.0503221102.
1.
Liu H, Golji J, Brodeur LK, et al. Tumor-derived IFN triggers chronic pathway agonism and sensitivity to ADAR loss. Nat Med. 2019;25(1):95-102. doi:10.1038/s41591-018-0302-5.
1.
Dutt A, Ramos AH, Hammerman PS, et al. Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS One. 2011;6(6):e20351. doi:10.1371/journal.pone.0020351.
1.
Yuan TL, Amzallag A, Bagni R, et al. Differential Effector Engagement by Oncogenic KRAS. Cell Rep. 2018;22(7):1889-1902. doi:10.1016/j.celrep.2018.01.051.
1.
Gallenne T, Ross KN, Visser NL, et al. Systematic functional perturbations uncover a prognostic genetic network driving human breast cancer. Oncotarget. 2017;8(13):20572-20587. doi:10.18632/oncotarget.16244.
1.
Dardaei L, Wang HQ, Singh M, et al. SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors. Nat Med. 2018;24(4):512-517. doi:10.1038/nm.4497.
1.
Fiziev P, Akdemir KC, Miller JP, et al. Systematic Epigenomic Analysis Reveals Chromatin States Associated with Melanoma Progression. Cell Rep. 2017;19(4):875-889. doi:10.1016/j.celrep.2017.03.078.